Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Keyword(s):
Key Points Complex karyotype and fludarabine refractoriness are key risk factors for progression of CLL on venetoclax. Bruton tyrosine kinase inhibitors are active in patients with CLL after prior therapy with venetoclax.
2019 ◽
Vol 3
(23)
◽
pp. 4021-4033
◽
2021 ◽
Vol 32
(12)
◽
pp. 1013-1031
Keyword(s):
2018 ◽
Vol 11
(9)
◽
pp. 749-756
◽
2016 ◽
Vol 101
(7)
◽
pp. 2733-2741
◽
Keyword(s):